Actively Recruiting
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-05-06
45
Participants Needed
16
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, BCOR-driven sarcoma, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01.
CONDITIONS
Official Title
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 6 years or older at the time of informed consent
- Age 2 years to under 6 years at the time of informed consent if PK cohort 1 is open; otherwise may enroll in phase 2
- Age 12 months to under 2 years at the time of informed consent if PK cohort 2 is open; otherwise may enroll in phase 2
- Signed informed consent by patient and/or parent or legally authorized representative; assent when appropriate
- Karnofsky score 60% or higher for patients older than 16 years; Lansky score 60 or higher for patients 16 years or younger
- Diagnosis of Wilms tumor or nephroblastoma in second or greater relapse, or refractory or first relapse with high risk histology, or refractory or first relapse after specific chemotherapy regimens
- Diagnosis of rhabdoid tumor including related subtypes, with failure to respond to at least one prior systemic therapy
- Diagnosis of progressive, relapsed, unresectable or metastatic MPNST with failure to respond to at least one prior systemic therapy
- Diagnosis of solid tumor (excluding hematologic malignancies) with evidence for selinexor benefit and failure to respond to at least one prior systemic therapy, with principal investigator approval
- Diagnosis of solid tumor with activating genomic alteration involving BCOR with principal investigator approval
- Measurable disease for phase II patients; evaluable or measurable disease for PK cohorts
- Adequate liver function within 14 days prior to treatment start
- Adequate kidney function within 14 days prior to treatment start
- Adequate blood counts within 14 days prior to treatment start
- Recovery from acute toxic effects of prior anti-cancer therapy and meeting specified washout periods
You will not qualify if you...
- Prior treatment with selinexor or another XPO1 inhibitor
- Uncontrolled infection; controlled infection within 1 week prior to treatment start is allowed
- Prior solid organ transplant
- Active treatment for graft-versus-host disease after allogeneic bone marrow transplant
- Medical, psychiatric, or social conditions that impair ability to comply with study requirements
- Pregnancy or breast-feeding
- Males or females of reproductive potential not agreeing to use two effective forms of birth control during the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 16 locations
1
Children's Hospital of Los Angeles (Data Collection Only)
Los Angeles, California, United States, 90027
Actively Recruiting
2
Stanford Medicine Children's Health (Data Collection Only)
Palo Alto, California, United States, 94304
Actively Recruiting
3
Children's National Hospital (Data Collection Only)
Washington D.C., District of Columbia, United States, 20010
Actively Recruiting
4
Children's Healthcare of Atlanta (Data Collection and Specimen Analysis)
Atlanta, Georgia, United States, 30322
Actively Recruiting
5
Ann & Robert H. Lurie Children'S Hospital of Chicag
Chicago, Illinois, United States, 60611
Actively Recruiting
6
Dana Farber Cancer Institute (Data Collection Only)
Boston, Massachusetts, United States, 02115
Actively Recruiting
7
Washington University
St Louis, Missouri, United States, 63110
Actively Recruiting
8
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, United States, 07920
Actively Recruiting
9
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, United States, 07748
Actively Recruiting
10
Memorial Sloan Kettering Bergen (Limited protocol activities)
Montvale, New Jersey, United States, 07645
Actively Recruiting
11
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities )
Commack, New York, United States, 11725
Actively Recruiting
12
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, United States, 10604
Actively Recruiting
13
Memorial Sloan Kettering Cancer Center (All protocol activites)
New York, New York, United States, 10065
Actively Recruiting
14
Memorial Sloan Kettering Nassau (Limited protocol activities)
Rockville Centre, New York, United States, 11553
Actively Recruiting
15
Cincinnati Children's Hospital Medical Center (Data collection only)
Cincinnati, Ohio, United States, 45229
Actively Recruiting
16
Cook Children's Health Care System (Data Collection Only)
Fort Worth, Texas, United States, 76104
Actively Recruiting
Research Team
M
Michael Ortiz, MD
CONTACT
J
Julia Glade Bender, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here